- Home
- ABVX vs ORIC Comparison
ABVX vs ORIC Comparison
Compare ABVX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVX
- ORIC
- Stock Information
- Founded
- ABVX 2013
- ORIC 2014
- Country
- ABVX France
- ORIC United States
- Employees
- ABVX N/A
- ORIC N/A
- Industry
- ABVX
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- ABVX
- ORIC Health Care
- Exchange
- ABVX Nasdaq
- ORIC Nasdaq
- Market Cap
- ABVX 722.3M
- ORIC 633.7M
- IPO Year
- ABVX N/A
- ORIC 2020
- Fundamental
- Price
- ABVX $6.16
- ORIC $9.58
- Analyst Decision
- ABVX Strong Buy
- ORIC Strong Buy
- Analyst Count
- ABVX 7
- ORIC 9
- Target Price
- ABVX $37.86
- ORIC $18.75
- AVG Volume (30 Days)
- ABVX 216.6K
- ORIC 597.6K
- Earning Date
- ABVX 09-09-2024
- ORIC 03-10-2025
- Dividend Yield
- ABVX N/A
- ORIC N/A
- EPS Growth
- ABVX N/A
- ORIC N/A
- EPS
- ABVX N/A
- ORIC N/A
- Revenue
- ABVX $9,676,417.00
- ORIC N/A
- Revenue This Year
- ABVX $31.67
- ORIC N/A
- Revenue Next Year
- ABVX $759.77
- ORIC N/A
- P/E Ratio
- ABVX N/A
- ORIC N/A
- Revenue Growth
- ABVX 100.87
- ORIC N/A
- 52 Week Low
- ABVX $5.54
- ORIC $6.33
- 52 Week High
- ABVX $17.02
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- ABVX 30.30
- ORIC 54.79
- Support Level
- ABVX $5.54
- ORIC $7.86
- Resistance Level
- ABVX $6.46
- ORIC $11.15
- Average True Range (ATR)
- ABVX 0.51
- ORIC 0.72
- MACD
- ABVX -0.04
- ORIC 0.23
- Stochastic Oscillator
- ABVX 30.10
- ORIC 52.28
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.